This study is looking at how well a medicine called vilobelimab works for people with a skin condition known as ulcerative pyoderma gangrenosum (PG). PG is a condition where painful sores or ulcers form on the skin. The study is a Phase III trial, which means it is a late-stage test to see if the treatment is effective and safe. Participants will be randomly assigned to receive either the vilobelimab medicine or a placebo, which is a harmless pill with no active medicine, without knowing which one they are getting. This helps ensure the study results are fair and unbiased.

Key Points:

• The study lasts for several weeks and involves multiple visits to the research center.
• Participants must be 18 years or older with at least one ulcer that can be measured.
• Participants should not have had certain treatments or vaccines recently.

Participants will be monitored to see how the ulcers respond to treatment and if there are any side effects. It's important to consider the time commitment and any potential risks before joining the study. If you have questions or need more information, talk to your doctor.